{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:20Z","timestamp":1783075940262,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1124\/jpet.119.256966","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T19:54:06Z","timestamp":1559764446000},"page":"278-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir"],"prefix":"10.1016","volume":"370","author":[{"given":"Matthew P.","family":"Kosloski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.J.","family":"Bow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1124\/jpet.119.256966_bib1","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.dld.2013.07.008","article-title":"The importance of drug-drug interactions in the DAA era","volume":"45","author":"Back","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1124\/jpet.119.256966_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijantimicag.2018.12.010","article-title":"Hepatitis C virus therapy: no one will be left behind","volume":"53","author":"Bourli\u00e8re","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/jpet.119.256966_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cpt.1213","article-title":"Dabigatran etexilate and digoxin: comparison as clinical probe substrates for evaluation of P-gp inhibition","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.256966_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.256966_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.256966_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.256966_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.119.256966_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"H\u00e4rtter","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.119.256966_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa\u00ae) after co-medication with verapamil in healthy subjects","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.119.256966_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","volume":"62","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1124\/jpet.119.256966_bib12","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0022-3565(25)39349-3","article-title":"Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney","volume":"266","author":"Hori","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"10.1124\/jpet.119.256966_bib13","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1124\/jpet.119.256966_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/00498254.2016.1233372","article-title":"Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions","volume":"47","author":"Kikuchi","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.119.256966_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.119.256966_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.256966_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.350","article-title":"Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study","volume":"7","author":"Lin","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/jpet.119.256966_bib18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jcph.959","article-title":"Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy White, Chinese, and Japanese adult subjects","volume":"57","author":"Lin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.119.256966_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.119.256966_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0002-9149(78)90997-9","article-title":"Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses","volume":"42","author":"Lloyd","year":"1978","journal-title":"Am J Cardiol"},{"key":"10.1124\/jpet.119.256966_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2334-12-86","article-title":"The high comorbidity burden of the hepatitis C virus infected population in the United States","volume":"12","author":"Louie","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1124\/jpet.119.256966_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt1976203253","article-title":"Digoxin bioavailability: formulations and rates of infusions","volume":"20","author":"Marcus","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.119.256966_bib23","series-title":"Package insert.","year":"2019"},{"key":"10.1124\/jpet.119.256966_bib24","doi-asserted-by":"crossref","first-page":"e02558","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.119.256966_bib25","doi-asserted-by":"crossref","first-page":"e01620","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4a protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.119.256966_bib27","series-title":"Summary of product characteristics","year":"2013"},{"key":"10.1124\/jpet.119.256966_bib28","series-title":"Package insert","year":"2015"},{"key":"10.1124\/jpet.119.256966_bib29","series-title":"Package insert","year":"2017"},{"issue":"Suppl 5","key":"10.1124\/jpet.119.256966_bib30","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/j.dld.2013.07.011","article-title":"Optimizing DAA management in daily practice","volume":"45","author":"Serfaty","year":"2013","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"10.1124\/jpet.119.256966_bib31","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1124\/jpet.119.256966_bib32","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1097\/MJT.0b013e31821106c9","article-title":"Dronedarone-induced digoxin toxicity: new drug, new interactions","volume":"20","author":"Vallakati","year":"2013","journal-title":"Am J Ther"},{"key":"10.1124\/jpet.119.256966_bib33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/mol.108.047647","article-title":"Human proximal tubular epithelium actively secretes but does not retain rosuvastatin","volume":"74","author":"Verhulst","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.256966_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/bph.12533","article-title":"Physiologically based pharmacokinetic modelling and in vivo [I]\/Ki accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate","volume":"171","author":"Zhao","year":"2014","journal-title":"Br J Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425936X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652425936X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.256966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:58:44Z","timestamp":1739980724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652425936X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S002235652425936X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.256966","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.256966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}